ERBB2 and breast cancer: Here, we develop a proof-of-principle strategy, using ErbB2 as a targeting receptor, to help facilitate the entry of a model NG-encapsulated therapeutic agent Doxorubicin into lysosomes of breast cancer cells by tampering with the biological mechanism that retards the delivery of ErbB2 into lysosomes.